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Abstract - More than 40 years after their 
introduction in therapy, 1,4-dihydropyridines (DHPs) 
are still amongst the most prescribed drugs in the 
world. Though they all share a similar mechanism of 
action blocking L-type voltage-gated Ca
2+
 channels, 
DHPs differ in crucial pharmacological properties like 
tissue selectivity and cardiodepressant activity. This 
review examines how changes in the DHP structure 
can modify the pharmacological properties of these 
drugs and how some of these chemical manipulations 
have been exploited to obtain clinically more effective 
molecules. Special emphasis is given to the evidence 
that L-type Ca
2+
 channels are an heterogeneous family 
and that DHPs with different pharmacological 
properties differ in their affinity for the different 
isoforms of this class of channels. Data showing that 
DHP pharmacological heterogeneity could be in part 
dependent on the interaction of some of these 
molecules with ion channels different from the L-type 
Ca
2+
 channels is reviewed as well.    
Key words: dihydropyridines, voltage-gated Ca
2+
 
channels, enantiomers, L-type channels, T-type 
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I.  INTRODUCTION 
 
Since their introduction in therapy more than 40 years 
ago [1], 1,4-dihydropyridines (DHPs) have been amongst 
the most successful drugs ever used in humans. Testifying 
this undeniable success amlodipine ranks amongst the 10 
most prescribed drugs in the United States [2] as in the 
rest of the world. Like phenylalkilamines and 
benzothiazepines, DHPs act by blocking L-type voltage 
gated Ca
2+
 [3]. These ion channels are multimeric protein 
composed by a pore forming 1 subunit and by accessory 
2,   and, variably,  subunits [4,5]. Among their many 
functional roles, L-type Ca
2+
 channels are crucial in 
controlling heart contractility and excitability [6], vascular 
tone [7] and the generation of spontaneous depolarizations 
in cardiac, neuronal or endocrine cells with pacemaking 
activity [8-10].  
DHPs differ from the other Ca
2+
 channel blockers 
because of their marked selectivity for vascular smooth 
cells respect to myocardium. This selectivity confers to 
DHPs the property of being good antihypertensive drugs 
with small or no cardiodepressant activity [11]. Two 
different mechanisms have been proposed to explain the 
higher DHP activity on blood vessels as compared with 
the heart: 1- an higher state-dependent affinity for the 
inactivated forms of L-type channels in vascular smooth 
muscle cells, and 2- the existence of two different 
isoforms of these channels, a cardiac isoform, exuisitely 
sensitive to phenylalkilamine inhibition, and a vascular 
smooth muscle cell isoform, preferentially inhibited by 
DHPs. The latter hypothesis has been formally 
demonstrated when different splicing variants of the 
CaV1.2 channel gene expressed in the heart and in 
vascular smooth muscle cells were identified [12-14]. The 
cardiac (CaV1.2a) and smooth muscle (CaV1.2b) isoforms 
differ in four different splicing loci: exon 1/1a in the N-
terminus, exon 8/8a in the transmembrane segment IS6, 
exon 31/32 in the transmembrane segment IVS3, and exon 
9* in the loop that connects domains I and II. Specifically, 
the exon composition of the cardiac and vascular smooth 
muscle cell isoform are the following: 1a/8a/9*/31/33 * 
[15], and 1/8/9*/ 32/33 [16], respectively. Importantly, 
when expressed in heterologous systems these two 
isoforms showed the different sensitivity to DHPs and 
other Ca
2+
 channel blockers observed in the heart and in 
blood vessels; in addition, mutagenesis studies showed 
that exon 8 in the IS6 region of the channel dictates DHPs 
selectivity  [13-14].  
Concerning the first hypothesis, i.e. that DHP could  
more active on vascular ion channels because they 
preferentially block inactivated Ca
2+
 channels in vascular 
smooth muscle cells, experiments performed with the 
cloned cardiac and vascular isoforms showed that gating 
differences cannot explain DHP tissue selectivity [17]. 
However, more recently, a splice variant that differs from 
the canonical CaV1.2b isoform because it lacks exon 33 
(CaV1.2SM: 1/8/9*/ 32/33) was identified in vascular 
smooth muscle cells and it was shown to be specifically 
sensitive to state-dependent inhibition by nifedipine  [18]. 
Therefore, the vascular districts expressing the CaV1.2SM 
isoform, DHPs could specifically display a more marked 
state/dependent block of L-type Ca2+ channels. 
A number of excellent reviews have been published 
on the structure,  mechanism of action and clinical uses of 
DHPs [for instance, 19-20]. Here, instead, we will focus 
on an interesting characteristic of this drug family, that 
has not been so extensively addressed in the literature: its 
pharmacological heterogeneity. While, indeed, all DHPs 
share a common molecular backbone and act on similar 
molecular targets, important differences do exist among 
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them both in their pharmacokinetic and pharmacodynamic 
properties. It has been proposed that the choice of the 
more appropriate DHP in specific clinical settings should 
take into account these differences that could also could 
influence the safety of each of these molecules.  
A first relevant pharmacodynamic difference among 
DHPs pertains tissue selectivity as classical observations 
showed that some DHPs could be more effective in 
relaxing some vascular beds than others. In particular, 
manidipine is relatively specific for renal vessels and 
seems to be a good choice in patients in which the 
preservation of a deranged renal function is the primary 
concern [21-22] and the same has been reported also for 
benidipine, efonidipine and nivaldipine [23]. In addition, 
nimodipine has been proposed to be quite selective for 
brain vessels and is recommended for the treatment of the 
vasospasm caused by subarhacnoid hemorragy [24-29], 
flunarizine is much more active on mesenteric artery than 
on the aorta [30] while nisoldipine is thought to be a 
relatively specific coronary vasorelaxant drug [31]. A 
second relevant pharmacodynamic difference concerns the 
effect on heart rate. Because of their predominant effect 
on blood vessels and of the fall in blood pressure that they 
cause, DHPs induce reflex tachycardia. However, 
important differences have been reported amongst the 
different members of this drug family in the entity of this 
tachycardic response. Specifically, isradipine and 
amplodipine are considered as the less tachycardic DHPs 
[32-34] and more recently cilnidipine was added to this 
list [35].   
Finally, some DHPs retain some negative inotropic 
activity that can be harmful especially when significant 
plasma concentrations are rapidly reached [36]. This 
eventuality appears more consistent with drugs of short 
half-life like nifedipine whose clinical use has found to be 
associated to an increase in the incidence of sudden deaths 
or cerebral ischemia [37-38]. DHPs differ, indeed, also in 
their pharmacokinetics and, in particular, in their half life. 
Taking into account both their half-life and 
cardiodepressant properties, DHPs have been traditionally 
classified in three different groups, or generations: 
cardiodepressant DHPs with a short half-life, 
cardiodepressant DHPs with a long half-life and non 
cardiodepressant DHPs with a long half life [39-40]. In 
Tab. 1 this classification has been modified to introduce a 
new group of non-cardiodepressant DHPs with ultra-short 
half-life that is exemplified by clevidipine. This new 
DHP, which has been approved by FDA in  2008,  
represents an important advancement in the treatment of 
hypertensive emergencies because it couples the lack of 
cardiodepressant activity with a very favourable 
pharmacokinetic profile with a rapid onset and 
disappearance of its effects [41-43].  
Considering that all DHPs share a similar mechanism 
of action as they block L-type Ca
2+
 channels, the question 
arises of establishing how and why different DHPs could 
be pharmacologically different. While this question is still 
open and object of investigation by several groups, the 
(few) data available seem to suggest that specific 
substitutions at key residues of the DHP backbone could 
affect the specificity of these drugs for CaV1.2 channels. 
Intriguingly,  DHP pharmacological profile can be 
significantly affected by structural changes lowering drug 
specificity an conferring them some activity on ion 
channels different from CaV1.2.  
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II. DIFFERENT PHARMACOLOGICAL 
PROPERTIES OF DIFFERENT DHPs: JUST A 
MATTER OF ION CHANNEL SELECTIVITY? 
 
A- THE CASE OF NON-TACHYCARDIC  DHPS 
Isradipine, amlodipine and cilnidipine are a good example 
of how a relative loss of selectivity could be responsible for the 
better pharmacological profile of some DHPs as compared with 
the other members of this family. As mentioned above, these 
DHPs have been described as less tachycardic than classical 
DHPs. This important pharmacological property can be 
explained on the basis of  their interaction with ion channels 
other than those encoded by the CaV1.2 gene. In particular, two 
other voltage-gated Ca2+ channel subtypes seem to be involved, 
the CaV1.3 and the CaV2.2-encoded channels. The CaV1.3 gene 
encodes for the pore forming subunit of the endocrine form of L-
type Ca2+ channels, formerly known as 1D [44]. CaV1.3 has a 
different distribution in the heart as compared with CaV1.2. 
While, indeed, CaV1.2 channels localize both in atria and in 
ventricles, CaV1.3 channels are expressed only in atria [45] and 
represent the main L-type channel form in sinoatrial node [46]. 
CaV1.3 channels differ from CaV1.2 channels because of a more 
negative threshold for activation and of a less marked voltage-
dependent inactivation [46-47]. Because of these biophysical 
properties CaV1.3 channels are well suited to take part in the 
generation of  repetitive depolarizations in pacemaker cells. 
Consistent with these data, severe bradyarrhythmias do occurr in 
CaV1.3 knock-out mice suggesting that this channel isoform is 
critical for cardiac pacemaking and for maintaining sinusal 
rhythm [10, 46, 48-50].  Importantly, this hypothesis is also 
supported by the results of electrophysiological studies 
performed on isolated SAN and AVN cells [10, 46, 48-50].  
While CaV1.3 channels have been shown to be less sensitive to 
DHPs than CaV1.2 channels [47], significant differences do exist 
among the different members of the DHP family as  isradipine, 
amlodipine and azidopine are at least 3-4 times more effective 
than nifedipine or nitrendipine in blocking CaV1.3 channels in 
vitro [51]. These results 
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Fig. 1 Differences in the spectrum of targets and pharmacological effects between CaV1.2 specific (classical) DHPs and less 
specific DHPs (mixed specificity DHPs). 
 
  
suggest that L-type Ca2+ currents in the sinoatrial and 
atrioventricular nodes are significantly blocked when either 
isradipine or, possibly, amlodipine are administered to 
hypertensive patients and this could explain why these drugs do 
not cause a significant reflex tachycardia (Fig. 1). Thus, specific 
DHPs may affect heart rate without exerting a significant 
negative inotropic activity. Confirming the hypothesis that 
negative inotropic and negative chronotropic effects could be 
dissociated in DHPs, among the different imidazo[2,1-b]thiazole 
DHP derivatives synthesized by Budriesi et al.   [52] some have 
a marked negative inotropic activity others a marked negative 
chronotropic activity and  others both. Interestingly, the ability 
to differentially affect contractility and rhythmicity in the 
myocardium has been demonstrated also in non-DHP 
compounds with L-type Ca2+channel blocking properties [53]. 
N-type channels Ca2+ channels whose pore forming unit is 
encoded by the CaV2.2 gene are the other channel type whose 
blockade could explain why some DHPs are less tachycardic 
than others. These Ca2+ channel subclass, is expressed in 
neuronal axon terminals where it controls the release of 
neurotransmitter including glutamate [54], γ-aminobutyric acid 
[55], acetylcholine [56], dopamine [57], and noradrenaline [58]. 
They have a special relevance in cardiovascular physiology as 
they control noradrenaline release in the orthosympathetic 
nervous system. This is demonstrated by the ability of the N/type 
blockers ω-conotoxin GVIA and ω-conotoxin MVIIA (SNX-
111) to inhibit noradrenaline release from superior cervical 
ganglia in vitro [59]  and to exert a sympatholytic activity in 
vivo [60], respectively. A formal demonstration that N-type 
channel activity is essential for the orthosympathetic  control of 
the cardiovascular system came from the evidence of its 
significant impairment in CaV 2.2 knock-out mice [61]. 
As shown by patch clamp experiments performed in 
heterologous expression systems with cloned CaV2.2 channels 
the vast majority of DHPs are virtually ineffective on N-type 
channels. However, a small DHP subgroup consisting of 
amlodipine, benidipine, cilnidipine, nicardipine, and barnidipine 
seems to stand apart from the others for it exerts some blockade 
of this channel type [62]. N-type channel blocking activity seems 
to be relevant for amlodipine ad cilnidipine with IC50s close to 
those for L-type channel blockade and in the low micromolar 
range [62]. Importantly, evidence that the orthosympathetic  
system is actually blocked in vivo has been reported for 
amlodipine and cilnidipine as these DHPs both decrease serum 
catecholamine levels and decrease heart rate variability in 
humans [63-66]. The ability of some DHPs like cilnidipine or 
amlodipine to exert a sympathicolytic activity  could be 
extremely helpful in improving the antihypertensive activity of 
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these drugs as it not only prevents reflex tachycardia but also 
other unwanted consequences of reflex authonomic activation 
like secondary hypereninemia of reflex peripheral 
vasoconstriction (Fig. 1). While the real relevance of N-type 
Ca2+ channel blockade in determining the clinical activity of 
amlodipine remains doubtful, some evidence that it could be 
crucial in the case of cilnidipine has been provided [35]. Before 
proceeding further we have, however, to remind that drug 
pharmacokinetic could also greatly influence the tachycardic 
reflex response elicited by DHP. DHPs with a long half-life only 
slowly reach effective plasma concentrations and, therefore, do 
not cause the sudden changes in blood pressure as those needed 
to trigger reflex tachycardia. This may be important in the case 
of amplodipine, which has a very long half-life of about 30 hours 
[67].  
 
B- THE CASE OF “NEFROPROTECTIVE”DHPS 
The small group of “nefroprotective” DHPs, including 
efonidipine, benidipine or manidipine, gives us an 
additional example of how some loss of selectivity could 
lead to  DHPs with pharmacological properties different 
from those observed in more CaV1.2-selective members of 
this family. Compelling  experimental evidences suggest, 
indeed, that the ability of this group of DHPs to 
preferentially increase renal blood flow is the 
consequence of their ability to significantly block another 
subclass of voltage/gated Ca
2+
 channels, the T-type 
channels. Also known as low-voltage activated Ca
2+
 
channels this channel family differs from HVA channels 
because of their permeation properties and because they 
open at much more negative potentials, inactivate more 
rapidly and deactivate more slowly [68-69]. Three 
different isoforms of T-type channels have been 
identified, CaV3.1, CaV3.2 and CaV3.3 which differ in 
their electrophysiological properties and tissue d 
istribution [69]. T-type channels also differ from L-type 
channels in their pharmacology. Though really selective 
T-type blockers are still missing, these channels are 
blocked by insect toxins like kurtoxins and Pro/Tx-I [70-
71], by neuroleptics [72], kinase inhibitors like imatinib 
mesylate [73] and non-steroidal anti-inflammatory drugs 
[74]. In addition, their gating behavior is profoundly 
affected by transition metals like Zn
2+
 [75]. While the 
majority of the DHPs are ineffective or only minimally 
effective on the different T-type isoforms, some of them 
strongly block these channels at concentrations close to 
those effective on L-type channels. Furukawa et al. [76] 
performed a  systematic analysis of the effects of several 
DHPs on CaV3.1, CaV3.2 and CaV3.3 channels 
heterologously expressed in Xenopus oocytes. Among the 
many DHPs tested, the most potent in blocking T/type 
channels were barnidipine, manidipine and amlodipine  
that, at 10 M concentrations, caused a 50% or higher 
current blockade; though less potent, also efonidipine, 
benidipine, and the old DHPs nifedipine and nicardipine  
displayed some T-type blocking effect [76]. Important 
differences were noted in the effect of these DHPs on the 
different CaV3 isoforms. In general, the above mentioned 
DHPs were more effective on CaV3.1 and CaV3.2 channels 
whereas they induced only a slight CaV3.3 blockade [76]. 
In addition, some DHPs like azelnipidine were more 
effective on CaV3.1 whereas others like manidipine were 
significantly more effective on CaV3.2 than on CaV3.1 
channels. Interestingly, nimodipine was almost ineffective 
on CaV3.1 but significantly inhibited CaV3.2 channels. 
The rank of  T-type blocking activity by different DHPs 
reported by Furukawa, however, may be highly dependent 
on the expression system used because different results 
were obtained when DHP effect on these channels were 
evaluated in HEK cells [77]. In particular, in these cells 
efonidipine, felodipine, isradipine, and nitrendipine 
behaved as potent T-type channel blockers and were 
almost tenfold more potent than amlodipine and 
nifedipine [77]. The ability of selected DHPs to 
significantly inhibit T-type channel activity has relevant 
pathophysiological implications in the kidney. It has been 
shown, indeed, that whereas L-type Ca
2+
 channels are 
preferentially located at the afferent arterioles, T-type 
channels are highly represented also at the efferent 
arterioles where they control vascular tone [78-80]. 
Specifically, by immunocitochemistry Poulsen et al. [80] 
showed that CaV3.1 is the prevalent T-type isoform in 
human glomerular vasculature. Consistent with the 
location of T-type but not L-type Ca
2+
 channels in the 
efferent arterioles, “pure” L-type blockers only dilate 
afferent arterioles whereas T-type blockers like mibefradil 
dilate both afferent and efferent arterioles [81-82] (Fig. 1). 
Thus, filtration pressure, tends to increase when a pure L-
type channel blockade is applied though this effect may be 
masked by the fall in systemic pressure [83-86]. 
Conversely, it  is markedly reduced by T-type channel 
blockers [79]. Therefore, according to the  hyperfiltration 
theory [87], which states that glumerular hypertension is a 
causative factor for the progression of chronic kidney 
disease (CKD),  drugs with T-type channel blocker 
properties are expected to display nefroprotective effects 
[88] and could be helpful in delaying CKD progression 
[89]. Importantly, it has been observed that DHPs with a 
relevant T-type channel blocking activity exert  favorable 
effects on the progression of CKD both in preclinical 
models of this disease and in humans. For instance,  this 
has been reported for efonidipine [90-97], benidipine [98-
104] and manidipine [105-111].  
Non-hemodynamic effects may have a role in 
conferring nefroprotective properties to T-type blocking 
DHPs. T-type  blockade [79]. Specifically, T-type 
channels control aldosterone synthesis in adrenocortical  
cells  [112-113] and T-type blocking  DHPs decrease 
aldosterone synthesis in vitro [114-115] (Fig. 1) and  
circulating aldosterone concentrations in hypertensive 
patients [91, 116-117]. In addition,  T-type channels seem 
to control mesangial proliferation [118]. Intriguingly, it 
has been reported that efonidipine significantly decreases 
tubulo-interstitial fibrosis in an experimental model of 
chronic unilateral ureteral obstruction in the rat, a 
pharmacological effect that has been attribute either to the 
decrease of aldosterone concentrations caused by these 
drugs or to their antioxidant properties [119]. 
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Considering the rich innervation by the noradrenergic 
system of both afferent and efferent arterioles, it is 
expected  that they are both vasodilated upon 
orthosympathetic pharmacological blockade. As a matter 
of fact, DHPs with combined N- and L-type Ca
2+
 channel 
blocking properties showed similar effect in a number of 
preclinical models in vivo and in vitro [120-123] and 
some evidence that thay could  exert nefroprotective 
effects also in human patients have been reported [124-
125] (Fig. 1). However, the entity of this effect seem to be 
considerably smaller than those of combined T- and L-
type blocking DHPs as showns by the few comparative 
studies available. For instance, benidipine performed 
better in nefroprotection than cinildipine or amlodipine 
[126-127]. 
A mixed T- and L-type blockade could be a much 
more effective pharmacological approach than pure L-
type blockade also in other clinical conditions. For 
instance, T-type channels are implicated in cardiac 
hypertrophy and in preclinical models mixed T- and L-
type Ca
2+
 channel blockers proved to be effective as 
antiremodelling agents [128-131] (Fig. 1). Concluding this 
section we would like to emphasize thanks to a small loss 
of selectivity, DHPs acting also on T-type channels 
acquire relevant new pharmacological properties and, 
paradoxically, tissue-selective effects.   
 
C- FURTHER MECHANISMS FOR SELECTIVE 
EFFECTS ON SPECIFIC VASCULAR BEDS? 
While the data reported in the previous section 
explain how some DHPs and not others may exert specific 
pharmacological effects in specific tissues, many pieces of 
information are still missing and we still do not have a 
definite explanation for other tissue-selective effects. 
However, a number of additional factors could be 
involved. In particular, it is now clear that the CaV1.2 L-
type Ca
2+
 channel family is much more complex that 
initially believed and that it encompasses much more 
members than just a cardiac and a smooth mucle cell 
isoform. As the CaV1.2 gene is composed by 55 exons, 19 
of which can be alternatively spliced, theoretically 219 
CaV1.2 L-type channel variants could be generated and 
approximately 40 of them have been actually identified 
[132]. The possibility that different splicing variants could 
be differently distributed in blood vessels of different 
tissues appears intriguing also considering that something 
similar has been demonstrated for other ion channels like 
voltage-gated K
+
 channels [133]. Unfortunately, a detailed 
mapping of their distribution of in different vascular beds 
is still missing and we ignore whether they differ in DHP 
sensitivity as well. However, we would like to mention 
that, as we mentioned above,  Liao et al. [18] identified a 
splice variant that differs from CaV1.2 because it lacks the 
33 exon and showed that it activates at more negative 
potentials than CaV1.2b, generates a window current and 
displays state-dependent block by nifedipine. 
Another possibility that remains unexplored is that the 
CaV1.3 channels subunit could be differentally expressed 
in different vascular compartments. It has been 
demonstrated, indeed, that this Ca
2+
 channels subtype, 
which, as reported above, differs from CaV1.2 in its 
sensitivity to DHPs, is expressed in vascular smooth 
muscle cells but its distribution in different vascular beds 
has not been systematically explored yet [134]. 
Finally, T-type channels are also expressed in other vascular 
districts besides the kidney such as the brain resistance vessels 
[134-136] and the pulmonary arterioles [137-138]. The 
pharmacological and clinical implications of these observations 
are still unclear and will represent, indubitably,  a rich area for 
future investigations. 
 
III. STRUCTURAL BASIS OF DHP FUNCTIONAL 
DIVERSITY. 
 
The evidence reported in the previous section 
suggests that the functional diversity of DHPs could be 
determined by subtle differences in the affinity either for 
channels other than CaV1.2 or, possibly, for different 
isoforms of CaV1.2 channels. They also raise, however, 
the question of how molecules with a similar structure 
could display such differences in target affinity. All the 
DHPs share, indeed, a similar basic structure consisting of 
an N-heterocyclyc pyridine ring bearing a phenyl 
substituent on its para-position. However, while the 
general three-dimensional structure of the molecule is 
believed to be preserved, both the N-heterocyclic ring and 
the benzene ring can be substituted in different positions 
giving rise to structurally different compounds (Fig.   ). 
Since the early `80s it has been known that the nature of 
the substituents both on the heterocylic and on the 
benzene ring affect potency and tissue selectivity of 
DHPs. Specifically, using the Hansch analysis for 
Quantitative Structure-Activity Analysis (QSAR) 
Rodenkirken et al. [139] showed that the position of 
phenyl ring substitution affects the cardiodepressant 
potency of DHPs in the cat papillary muscle preparation. 
In particular, the DHPs whose phenyl ring is substituted in 
position ortho are the most cardiodepressant, those with 
substituents in position para the less cardiodepressant 
whereas metha-substituted compounds rank in-between 
[139]. The effect of the phenyl-substituents depends also 
on steric factors since the cardiodepressant activity 
increases with the width of the substituent. Similar results 
were obtained when the potency in relaxing  guinea pig 
ileal preparations was measured [140].  
While phenyl ring substitutions seem to affect mainly 
DHP potency, ester chain substitutions on the heterocylic 
ring influence not only the potency but also  the selectivity 
of these drugs. In particular, vascular selectivity seems to 
increase with the size of the substituent. So niludipine 
[141] and nisoldipine [142], not only have much bigger 
side chain substituents on the heterocyclic ring but also a 
much higher vascular selectivity than nifedipine. 
Similarly, benidipine [143] and nicardipine [144], two 
DHPs with very large side chains, have a very favorable 
pharmacological profile with high vascular selectivity.  
Kojda et al. [145]  explored the effect of lengthening the 
side chain ester substituents in nitrendipine derivatives 
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and found that a small increase in side chain length (up to 
3-I-propil-ester) determines an increase in vasodilator 
potency which did not correlate with the lipophylicity but 
with the charge of the side chain. 
The substitution of the heterocyclic ring on position 3 
and 5 has also another important structural consequence 
which can affect DHP potency and selectivity: whenever 
the residues on these two positions are not identical the 
DHP molecule bocomes chiral. In fact, the carbon 4 
becomes a chiral center and two different optical 
enantiomers will exist for this DHP molecule. Starting 
from the observation that verapamil, a calcium channel 
blocker belonging to the family of phenylalkilamine, is 
also a chiral molecule and that its two enantiomers display 
a different potency in blocking L-type calcium channel 
[146], a few years after the synthesis of the first 
asymmetrically substituted DHPs,  Towart et al. [147] 
looked at the potency of the enantiomers of a series of 
chiral DHPs. They found that exactly as in the case of 
verapamil, the two enantiomers of chiral DHPs display 
markedly different potencies. Since there, a number of 
studies confirmed and extended this observation. Clear 
differences in the potency of the two optical enantiomers 
of chiral DHPs have been described in a number of 
studies. For example, Shibanuma et al. [148] showed that 
two enantiomers of nicardipine display a different potency 
in lowering the blood pressure in the dog. Amlodipine 
[149] and nimodipine [150] enantiomers differ in their 
ability to induce the relaxation of high potassium-
precontracted aorta strips in vitro. Similarly, manidipine 
[151] and benidipine (Muto et al., 1988) enantiomers 
display a different potency in lowering the blood pressure 
in rats. Inagaki et al. [152] examined in anestesized dogs 
the pharmacological activity of a the optical enantiomers 
of barnidipine, a DHP with two chiral centers, and found 
differences in the potency of its four stereoisomers with a 
potency order that agreed with that reported in vitro. A 
limited number of studies suggest that differences in 
potency between the different enantiomers of chiral DHPs 
similar to those observed in experimental animals could 
also exist in humans. For instance, Mikus et al. [153] 
examined the blood pressure lowering activity of the two 
nitrendipine enantiomers in healty volunteers and 
confirmed that the pharmacological activity of this drug is 
almost completely due to the S-enantiomer. Soons et al 
have obtained similar results [154] comparing the effects 
of the two enantiomers of felodipine and nitrendipine and 
of their racemic mixtures in young, healthy males.  
Very limited data suggest that DHP chirality could 
also influence tissue selectivity. In particular, this has 
been observed for the two optical isomers of isradipine 
[155] because in anesthesized cats the S-enantiomer of 
this DHP is much more effective in lowering systemic 
pressure and heart rate than R-enantiomer, which, instead, 
is more potent in increasing subendocardial flux. 
Intriguingly, evidence of a role of the enantiomeric 
configuration in influencing tissue selectivity has been 
reported also for non-DHP chiral calcium channel 
blockers like verapamil [156]. 
 
 
Fig. 2 Different kinetics of L-type channel blockade by the two enantiomers of Nitrendipine and Manidipine. The 
panel on the right shows [Ca2+]I response to high K+ in GH3 cells. The decay phase of this response upon 
administration of the different enantiomers ireported in the two panels on the left (From Cataldi et al., Eur. J. Pharmacol. 
vol. 376, no. 1-2, pp. 169-178, Jul 1999). 
 
 
Translational Medicine @ UniSa, - ISSN 2239-9747 2012, 3(4): 12-26 
 
18 
Università degli Studi di Salerno 
Several mechanisms could determine the differences 
in potency and/or tissue selectivity observed among 
different enatiomers of the same DHPs. First, differences 
in potency in couples of DHP enantiomers could be 
determined by differences in the affinity for L-type 
channels. For instance, it has been shown that in 
radioligand studies the less potent enantiomer of 
nicardipine [157], manidipine [151], niguldipine [158] 
and benidipine [159] show a reduced affinity for these 
channels. As we mentioned above, some DHPs may also 
interact with CaV channel isoform different from CaV1.2 
L-type channels and this could be relevant in determining 
tissue-specific effects of these compounds. In this 
perspective, it interesting to emphasize that T-type 
channel blockade both by efonidipine and by benidipine is 
stereoselective with R-efonidipine and S-benidipine being 
much more potent than their enantiomeric counterparts 
[160-161]. This suggests that differences in tissue 
selectivity among DHP enantiomers could mirror 
differences in the choreography of the ion channels 
blocked by these drugs. 
 It is also intriguing that relevant differences in the 
kinetics of Ca
2+
 channel blockade have been reported 
among different DHP enantiomers. For instance, great 
differences were observed in the time of onset and 
disappearance of the increase in coronary blood flow 
observed after the intracoronary administration of the four 
enantiomers of barnidipine [152]. While this represents 
only a very indirect indication of a different activity on L-
type Ca
2+
 channels more direct evidences have bee 
reported. In particular, we used a microfluorimetric 
approach in fura-2 loaded pituitary GH3  cells to evaluate 
the kinetics of the inhibitory effect of the enantiomers of  
nitrendipine and manidipine on the increase in [Ca
2+
]i 
elicited by membrane depolarization with an high K
+
 
solution [162]. In control conditions this stimulus elicited 
a biphasic [Ca
2+
]i response consisting of a first fast spike 
flowed by a long lasting plateau (Fig. 2). Nitrendipine and 
manidipine affected both these phases by lowering the 
spike and accelerating the decay of the plateau. However,  
in both cases, the more active S enantiomer almost 
exclusively blocked the fast spike without significantly 
affect the plateau phase channels whereas the less active 
R enantiomers only accelerated the decay of the plateau 
without affect the spike [162] (Fig. 2).  In patch clamp 
experiments, this corresponded to a significantly longer 
time to maximal current inhibition in R as compared with 
S/enantiomers. Similar results were also obtained with the 
two optical isomers of lercanidipine [163] (Fig. 2). The 
differences that we observed could be possibly explained 
in terms of a differential affinity of the two optical 
isomers of the tested DHPs for open and inactivated Ca
2+
 
channels according to the guarded receptor hypothesis 
similarly to what observed by Handrock et al. [164] for 
the two enantiomers of isradipine. By whole cell 
electrophysiology, they found, indeed, that the less potent 
enantiomer of isradipine, (-)-isradipine, preferentially 
blocks the Ba
2+
 currents flowing through L-type Ca
2+
 
channels in the late phases of a depolarizing pulse when 
many channels are inactivated whereas the more active 
(+)-isradipine preferentially induces a block during the 
early phase of the pulse when the majority of the channels 
are in an open state. 
 
IV. CONCLUSIONS AND FUTURE 
PERSPECTIVES 
 
In conclusion, though sharing a similar mechanism of 
action and a common main binding site on voltage gated 
CaV1.2 Ca
2+
 channels, DHPs are actually an 
heterogeneous drug family with relevant differences in 
potency, tissue selectivity and pharmacokinetics. Here, we 
put the emphasis on the evidence that part of this 
heterogeneity originates from activities exerted on ion 
channels diverse from CaV1.2. However, additional 
“unintended” pharmacological activities have been 
described in selected DHPs [165-166]. For instance, a 
number of marketed DHPs like nimodipine, felodipine 
and benidipine may have mineralcorticoid antagonistic 
properties [167-168]. Interestingly, this pharmacological 
activity is markedly dependent on the enantiomeric 
configuration [169] and it could be relevant in conferring 
to these drugs the ability to exert antiremodelling effects 
[170] (Fig. 1). Moreover, selected DHPs including 
amlodipine, azelnidipine, benidipine or cinildipine 
enhance the release of nitric oxide from the endothelium 
and exert antioxidant effects [171-179]. Additional 
pharmacological properties such as a combined  and -
adrenergic antagonistic activity [180-181] or NO-donor 
properties [182] may be conferred to DHPs by rationally 
designed modifications. In conclusion,  modifications of 
the backbone of CaV1.2 blocking DHPs can confer to 
these drugs additional, clinically relevant pharmacological 
activities. By improving our understanding of the 
mechanisms involved more and more effective new 
compounds can be designed so rejuvenating this 
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